[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1113963T1 - Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος - Google Patents

Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος

Info

Publication number
CY1113963T1
CY1113963T1 CY20121101076T CY121101076T CY1113963T1 CY 1113963 T1 CY1113963 T1 CY 1113963T1 CY 20121101076 T CY20121101076 T CY 20121101076T CY 121101076 T CY121101076 T CY 121101076T CY 1113963 T1 CY1113963 T1 CY 1113963T1
Authority
CY
Cyprus
Prior art keywords
activia
competitors
prevention
pharmaceutical compositions
aspects
Prior art date
Application number
CY20121101076T
Other languages
English (en)
Inventor
John Knopf
Jasbir Seehra
Ravindra Kumar
Original Assignee
Acceleron Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma, Inc. filed Critical Acceleron Pharma, Inc.
Publication of CY1113963T1 publication Critical patent/CY1113963T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/08—Mobility data transfer
    • H04W8/082—Mobility data transfer for traffic bypassing of mobility servers, e.g. location registers, home PLMNs or home agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W40/00—Communication routing or communication path finding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W80/00—Wireless network protocols or protocol adaptations to wireless operation
    • H04W80/04—Network layer protocols, e.g. mobile IP [Internet Protocol]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W84/00—Network topologies
    • H04W84/18—Self-organising networks, e.g. ad-hoc networks or sensor networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L2212/00—Encapsulation of packets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Σε ορισμένες απόψεις, η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για την προαγωγή οστικής ανάπτυξης και την αύξηση της οστικής πυκνότητας, καθώς επίσης για τη θεραπευτική αγωγή πολλαπλού μυελώματος.
CY20121101076T 2007-02-09 2012-11-12 Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος CY1113963T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90058007P 2007-02-09 2007-02-09
US93276207P 2007-05-31 2007-05-31
US93736507P 2007-06-26 2007-06-26
US52807P 2007-10-25 2007-10-25
EP08725055A EP2120999B1 (en) 2007-02-09 2008-02-01 Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma

Publications (1)

Publication Number Publication Date
CY1113963T1 true CY1113963T1 (el) 2016-07-27

Family

ID=39690668

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101076T CY1113963T1 (el) 2007-02-09 2012-11-12 Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος

Country Status (25)

Country Link
US (4) US8173601B2 (el)
EP (3) EP2481415B1 (el)
JP (6) JP5574711B2 (el)
KR (7) KR20160129095A (el)
CN (3) CN104548056B (el)
AR (1) AR065289A1 (el)
AU (1) AU2008216896B2 (el)
BR (1) BRPI0807506B1 (el)
CA (3) CA2913992C (el)
CY (1) CY1113963T1 (el)
DK (1) DK2120999T3 (el)
EA (3) EA201690994A1 (el)
ES (2) ES2394123T3 (el)
HK (1) HK1137366A1 (el)
HR (1) HRP20120947T1 (el)
IL (3) IL200242B (el)
ME (1) ME02333B (el)
MX (2) MX368173B (el)
PL (1) PL2120999T3 (el)
PT (1) PT2120999E (el)
RS (1) RS52535B (el)
SI (1) SI2120999T1 (el)
TR (1) TR200906329T1 (el)
TW (7) TWI606062B (el)
WO (1) WO2008100384A2 (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
KR101585623B1 (ko) 2005-11-23 2016-01-19 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
PL2124999T3 (pl) 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
CN101861161B (zh) * 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
EP3804746A1 (en) 2008-06-26 2021-04-14 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
WO2009158035A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP2475427B1 (en) * 2009-09-09 2016-11-30 Acceleron Pharma, Inc. Actriib antagonists and dosing and uses thereof
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
KR20120115602A (ko) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 골 관련 암의 치료
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP2914277B1 (en) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
EP4480582A1 (en) 2013-01-18 2024-12-25 Biomeme, Inc. Analytic device
DK2976359T4 (da) * 2013-03-20 2022-06-13 Genzyme Corp Fremgangsmåder til behandling af osteogenesis imperfecta
JP2015159766A (ja) * 2014-02-27 2015-09-07 国立大学法人京都大学 クッシング症候群の検査方法、検査用バイオマーカー及び治療剤
WO2015161220A1 (en) 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
MX2016016531A (es) 2014-06-13 2017-04-25 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de las ulceras.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
CA2986432A1 (en) 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
CN108697793B (zh) * 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
MX2019000618A (es) * 2016-07-15 2019-11-28 Acceleron Pharma Inc Composiciones y metodos para tratar hipertension pulmonar.
CN119241685A (zh) 2016-11-10 2025-01-03 科乐斯疗法公司 激活素受体iia型变体及其使用方法
GB201620119D0 (en) 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
AU2018214979A1 (en) * 2017-02-01 2019-08-15 Acceleron Pharma Inc. TGFβ and actrii antagonists for use in increasing immune activity
CN110461359B (zh) 2017-03-24 2025-01-21 诺华股份有限公司 用于预防和治疗心脏病的方法
CN111356768A (zh) 2017-09-15 2020-06-30 生米公司 用于自动化样品处理的方法和系统
CN111801112A (zh) * 2017-11-09 2020-10-20 科乐斯疗法公司 激活素受体iia型变体及其使用方法
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
WO2019213016A1 (en) 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
WO2020022782A1 (ko) * 2018-07-24 2020-01-30 주식회사 굳티셀 면역 관련 질환의 예방 또는 치료용 조성물
WO2020191193A1 (en) 2019-03-21 2020-09-24 Biomeme, Inc. Multi-function analytic devices
AU2021245671A1 (en) 2020-03-31 2022-10-20 Cell Exosome Therapeutics Inc. Cell preservation method
WO2022061105A1 (en) 2020-09-18 2022-03-24 Biomeme, Inc. Portable devices and methods for analyzing samples
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
EP0548276A4 (en) 1990-09-13 1993-12-29 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
CA2153652A1 (en) * 1993-01-12 1994-07-21 Se-Jin Lee Growth differentiation factor-3
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
EP0771873A3 (en) * 1995-10-27 1998-03-04 Takeda Chemical Industries, Ltd. Neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) * 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) * 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
KR20000052807A (ko) 1996-10-25 2000-08-25 윌리암스 로저 에이 순환 교환된 에리트로포이에틴 수용체 아고니스트
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US6300127B1 (en) 1997-07-30 2001-10-09 Emory University Bone mineralization proteins, DNA, vectors, expression systems
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
KR100473836B1 (ko) 1997-10-03 2005-03-07 츄가이 세이야꾸 가부시키가이샤 천연 인간형화 항체
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US6440930B1 (en) 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
US6656708B1 (en) * 1998-09-22 2003-12-02 Long Yu Human growth differentiation factor encoding sequence and polypeptide encoded by such DNA sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN1163262C (zh) * 1999-04-01 2004-08-25 上海益众生物技术有限公司 成骨生长肽药物组合物及制备方法和应用
WO2000062809A1 (fr) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
NZ519546A (en) 1999-12-15 2005-07-29 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US20030215913A1 (en) 2000-07-19 2003-11-20 Enrique Alvarez Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US7048949B2 (en) 2000-11-20 2006-05-23 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
WO2002043759A2 (en) 2000-12-01 2002-06-06 Wyeth Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
SI2116259T1 (sl) 2001-05-24 2012-11-30 Zymogenetics Inc Taci imunoglobulin fuzijski proteini
CA2448253A1 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US7396642B2 (en) 2001-07-17 2008-07-08 Teijin Limited Methods of screening for a compound that enhances thermogenesis
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP1573002A4 (en) 2002-02-11 2008-07-16 Genentech Inc ANTIBODY VARIANTS WITH ACCELERATED ANTIGEN ASSOCIATED SPEEDS
WO2003072715A2 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1: a follistatin domain containing protein
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
AU2003232485A1 (en) 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004016639A1 (en) 2002-08-16 2004-02-26 Wyeth Bmp-2 estrogen responsive element and methods of using the same
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
DE602004018902D1 (de) 2003-02-07 2009-02-26 Prometic Biosciences Inc Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
WO2004086953A2 (en) 2003-03-26 2004-10-14 The Board Of Trustees Of The University Of Arkansas Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
UA85055C2 (ru) 2003-06-02 2008-12-25 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
ES2330860T3 (es) 2004-01-22 2009-12-16 Merck Patent Gmbh Anticuerpos anticancerosos con fijacion del complemento reducida.
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
JP2007530055A (ja) * 2004-03-26 2007-11-01 アクセルロン ファーマ インコーポレーテッド Ｂｍｐ−３プロペプチドおよび関連する方法
EP1730186A2 (en) 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 variants with improved properties
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
EP1755648A2 (en) * 2004-05-27 2007-02-28 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
US7465706B2 (en) 2004-06-24 2008-12-16 Acceleron Pharma Inc. GDF3 propeptides and related methods
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
WO2006015368A2 (en) 2004-08-05 2006-02-09 The Regents Of The University Of California Molecules with effects on cellular development and function
CA2575563A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
EP1804824B1 (en) 2004-09-29 2017-01-04 Icahn School of Medicine at Mount Sinai Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
MX2007005884A (es) 2004-11-16 2008-02-12 Amgen Mountain View Inc Andamios de proteina y usos de los mismos.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1858541B1 (en) 2005-02-16 2012-07-25 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
US20060213667A1 (en) * 2005-03-28 2006-09-28 Mashburn Benny D Screen apparatus and method
KR20080003929A (ko) 2005-04-26 2008-01-08 아지노모토 가부시키가이샤 골수 적혈구 전구 세포 분화 촉진제
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
BRPI0616589A2 (pt) 2005-09-28 2011-06-28 Zymogenetics Inc polipeptìdeo, e, métodos para produzir um anticorpo para um polipeptìdeo, para reduzir ou inibir a inflamação e para tratar um mamìfero afligido com uma doença inflamatória
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR101585623B1 (ko) * 2005-11-23 2016-01-19 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한이들의 용도
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
EP1973909A2 (en) 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
US7361510B2 (en) * 2006-01-20 2008-04-22 Beckman Coulter, Inc. Methods of detection of iron deficiency
JP2009531280A (ja) 2006-01-25 2009-09-03 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物
CN101394738A (zh) 2006-02-28 2009-03-25 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
WO2007120767A2 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
US20080075692A1 (en) * 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
WO2008011126A2 (en) * 2006-07-21 2008-01-24 Lyne Laboratories Liquid compositions of calcium acetate
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
EP2103628A4 (en) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
PL2124999T3 (pl) * 2006-12-18 2013-03-29 Acceleron Pharma Inc Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
WO2008094708A2 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
JP2010529041A (ja) 2007-06-01 2010-08-26 ワイス・エルエルシー Ｂｍｐ−１０活性を調整する方法および組成物
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009019504A1 (en) 2007-08-03 2009-02-12 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
MX2010005656A (es) 2007-11-21 2010-11-12 Amgen Inc Anticuerpos y epitopos de enlace wise.
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
FR2930460B1 (fr) * 2008-04-25 2010-05-28 Valois Sas Distributeur de fragrance.
CA2725208A1 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
WO2009158035A2 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
EP3804746A1 (en) 2008-06-26 2021-04-14 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010059861A1 (en) 2008-11-20 2010-05-27 University Of Southern California Compositions and methods to modulate hair growth
AR074397A1 (es) 2008-11-26 2011-01-12 Amgen Inc Polipéptidos receptores de activina iib estabilizados y usos de los mismos
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
PT2424895T (pt) * 2009-04-27 2017-12-15 Novartis Ag Composições e métodos para aumentar o crescimento muscular
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102606494B1 (ko) 2009-08-13 2023-11-24 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
EP2475427B1 (en) 2009-09-09 2016-11-30 Acceleron Pharma, Inc. Actriib antagonists and dosing and uses thereof
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
US9365651B2 (en) 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
AU2012326207B2 (en) 2011-10-17 2016-12-15 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
US20140303068A1 (en) 2011-10-28 2014-10-09 Paranta Biosciences Limited Method of treating mucus hypersecretion
SG10201605027XA (en) 2011-12-19 2016-08-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9663569B2 (en) 2012-06-14 2017-05-30 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
WO2014007198A1 (ja) 2012-07-02 2014-01-09 協和発酵キリン株式会社 抗ｂｍｐ９抗体を有効成分とする、腎性貧血、がん性貧血などの貧血に対する治療剤
WO2014066487A2 (en) 2012-10-24 2014-05-01 Celgene Corporation Methods for treating anemia
JP6401171B2 (ja) 2012-10-24 2018-10-03 セルジーン コーポレイション 貧血の治療に使用するためのバイオマーカー
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
EP2914277B1 (en) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
MX2015005839A (es) 2012-11-08 2015-12-17 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
BR112016002198A2 (pt) 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
EP3084000A4 (en) 2013-12-16 2017-09-20 Paranta Biosciences Limited Method of diagnosis and treatment
WO2015108972A1 (en) 2014-01-14 2015-07-23 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
US10260068B2 (en) 2014-03-31 2019-04-16 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva
WO2015161220A1 (en) 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados

Also Published As

Publication number Publication date
CN104548056B (zh) 2022-09-09
EA200970747A1 (ru) 2010-02-26
HRP20120947T1 (hr) 2012-12-31
EP2120999B1 (en) 2012-08-29
TR200906329T1 (tr) 2010-01-21
TW201500371A (zh) 2015-01-01
TWI525102B (zh) 2016-03-11
EP2481415A1 (en) 2012-08-01
ES2394123T3 (es) 2013-01-22
US20130004489A1 (en) 2013-01-03
DK2120999T3 (da) 2012-12-03
EP2120999A2 (en) 2009-11-25
PL2120999T3 (pl) 2013-01-31
AU2008216896B2 (en) 2013-06-20
KR20160129095A (ko) 2016-11-08
CA2677605A1 (en) 2008-08-21
JP2018162312A (ja) 2018-10-18
RS52535B (en) 2013-04-30
EP2484372A1 (en) 2012-08-08
KR20200054317A (ko) 2020-05-19
EA201690994A1 (ru) 2016-09-30
IL200242A0 (en) 2010-04-29
MX2009008510A (es) 2010-01-15
KR20210082540A (ko) 2021-07-05
CN101687016B (zh) 2014-12-31
HK1137366A1 (en) 2010-07-30
TW201934141A (zh) 2019-09-01
CN101687016A (zh) 2010-03-31
KR101672156B1 (ko) 2016-11-02
JP2013224317A (ja) 2013-10-31
TW201907953A (zh) 2019-03-01
CN104548056A (zh) 2015-04-29
TW200900076A (en) 2009-01-01
CA2677605C (en) 2016-01-19
SI2120999T1 (sl) 2012-12-31
TWI606062B (zh) 2017-11-21
ME02333B (me) 2013-04-30
TWI667038B (zh) 2019-08-01
KR20180083967A (ko) 2018-07-23
KR101670417B1 (ko) 2016-11-10
WO2008100384A2 (en) 2008-08-21
US9572865B2 (en) 2017-02-21
US20210261682A1 (en) 2021-08-26
WO2008100384A3 (en) 2008-12-11
CA3039330C (en) 2021-11-09
MX368173B (es) 2019-09-23
IL257848B (en) 2021-04-29
EA025371B1 (ru) 2016-12-30
EA201300116A1 (ru) 2013-09-30
CA2913992A1 (en) 2008-08-21
JP2015091870A (ja) 2015-05-14
ES2756725T3 (es) 2020-04-27
KR20100014850A (ko) 2010-02-11
TW201615660A (zh) 2016-05-01
CN104189889A (zh) 2014-12-10
JP6132861B2 (ja) 2017-05-24
US20170190784A1 (en) 2017-07-06
TWI459963B (zh) 2014-11-11
KR20190026047A (ko) 2019-03-12
IL257848A (en) 2018-04-30
BRPI0807506B1 (pt) 2022-02-15
US20090142333A1 (en) 2009-06-04
JP2017071624A (ja) 2017-04-13
CA2913992C (en) 2019-05-21
CA3039330A1 (en) 2008-08-21
TW201808334A (zh) 2018-03-16
AU2008216896A1 (en) 2008-08-21
EA018221B1 (ru) 2013-06-28
EP2481415B1 (en) 2019-09-11
AU2008216896A2 (en) 2011-07-14
IL200242B (en) 2018-03-29
US8173601B2 (en) 2012-05-08
TW202140531A (zh) 2021-11-01
AR065289A1 (es) 2009-05-27
KR20150115965A (ko) 2015-10-14
PT2120999E (pt) 2012-12-10
IL281715A (en) 2021-05-31
JP2010518079A (ja) 2010-05-27
JP5574711B2 (ja) 2014-08-20
BRPI0807506A2 (pt) 2013-07-30
JP2020176139A (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
EA200801406A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
CY1118472T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200870569A1 (ru) Соединения и способы модуляции fxr
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1111123T1 (el) Μεθοδοι χρησης υποδοχεα gpr119 για να πιστοποιουνται ενωσεις χρησιμες για αυξηση οστικης μαζας σε ενα ατομο
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1113413T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1118179T1 (el) Φαρμακευτικη συνθεση
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
MY156691A (en) 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1